Page last updated: 2024-12-11

nileprost

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nileprost: stable prostacyclin analog; RN given refers to (E)-(3aR,4R,5R,6aS)(E)-(3S,4RS)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6436100
CHEMBL ID2104724
SCHEMBL ID6730984
MeSH IDM0116684

Synonyms (15)

Synonym
nileprost
zk-34798
(5e)-5-[(3ar,4r,5r,6as)-5-hydroxy-4-[(e,3s)-3-hydroxy-4-methyloct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]-5-cyanopentanoic acid
ygd81bg4sn ,
nileprostum [inn-latin]
unii-ygd81bg4sn
(e)-(3ar,4r,5r,6as)-delta-cyano-3,3a,4,5,6,6a-hexahydro-5-hydroxy-4-((e)-(3s,4rs)-3-hydroxy-4-methyl-1-octenyl)-2h-cyclopenta(b)furan-delta(sup 2,delta)-valeric acid
nileprost [inn]
nileprostum
71097-83-1
CHEMBL2104724
(e)-(3ar,4r,5r,6as)-.delta.-cyano-3,3a,4,5,6,6a-hexahydro-5-hydroxy-4-((e)-(3s,4rs)-3-hydroxy-4-methyl-1-octenyl)-2h-cyclopenta(b)furan-.delta.(sup 2,.delta.)-valeric acid
SCHEMBL6730984
Q27294512
DTXSID501024482

Research Excerpts

Overview

Nileprost is a new prostacyclin analogue stabilized by introduction of the cyano group at its 5-position.

ExcerptReferenceRelevance
"Nileprost is a new prostacyclin analogue stabilized by introduction of the cyano group at its 5-position. "( Degradation and isomerization of nileprost, 5-cyano-16-methyl-prostacyclin, in aqueous solution.
Ohkawa, Y; Yoneda, M, 1990
)
2

Pharmacokinetics

ExcerptReferenceRelevance
" 3H-Nileprost was absorbed after oral administration with a half-life of 23 min reaching maximum concentrations in the plasma 90 min after treatment."( Pharmacokinetics of the stable prostacyclin analogue, nileprost, in the rat.
Krause, W; Schulze, PE; Totzek, M, 1983
)
1.07
" The disposition half-life was 5-7 h in both cases."( Development of a radioimmunoassay and its application to the pharmacokinetics of the stable prostacyclin analogue, nileprost, in the rat.
Krause, W; Nieuweboer, B, 1984
)
0.48

Bioavailability

ExcerptReferenceRelevance
" Bioavailability of nileprost was calculated to be 21 and 13% of the dose."( Development of a radioimmunoassay and its application to the pharmacokinetics of the stable prostacyclin analogue, nileprost, in the rat.
Krause, W; Nieuweboer, B, 1984
)
0.8
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (55.56)18.7374
1990's4 (44.44)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.11 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]